Top Page
CARsgen Therapeutics Holdings Ltd.
(2171)
CARsgen Therapeutics Holdings Ltd. (2171) vs. iShares MSCI Hong Kong ETF (EWH)
CARsgen Therapeutics Holdings Ltd. Business Overview & Revenue Model
CARsgen Therapeutics Holdings Ltd. Financial Statement Overview
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 122.41M | 39.42M | 0.00 | 0.00 | 25.81M |
| Gross Profit | 49.15M | 14.75M | -96.57M | -94.81M | 25.81M |
| EBITDA | -200.42M | -686.61M | -717.64M | -748.73M | -4.67B |
| Net Income | -95.33M | -798.13M | -747.79M | -892.25M | -4.74B |
Balance Sheet | |||||
| Total Assets | 1.29B | 1.67B | 2.26B | 2.76B | 3.51B |
| Cash, Cash Equivalents and Short-Term Investments | 1.12B | 1.48B | 1.85B | 2.27B | 3.01B |
| Total Debt | 61.20M | 166.42M | 85.22M | 119.44M | 338.05M |
| Total Liabilities | 513.02M | 616.33M | 455.51M | 289.64M | 508.98M |
| Stockholders Equity | 779.67M | 1.06B | 1.80B | 2.47B | 3.00B |
Cash Flow | |||||
| Free Cash Flow | 0.00 | -429.26M | -464.48M | -781.66M | -690.77M |
| Operating Cash Flow | -230.77M | -409.69M | -454.94M | -643.05M | -512.32M |
| Investing Cash Flow | -2.81M | 12.52M | 39.25M | 2.39B | -2.47B |
| Financing Cash Flow | -108.83M | 18.46M | -22.14M | -236.51M | 2.67B |
CARsgen Therapeutics Holdings Ltd. Technical Analysis
CARsgen Therapeutics Holdings Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$22.16B | 42.36 | 15.32% | ― | 48.38% | ― | |
64 Neutral | HK$10.08B | 20.83 | 6.69% | 4.28% | -8.49% | -9.46% | |
54 Neutral | HK$15.81B | -22.61 | -12.74% | ― | -76.58% | -4.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$8.94B | -77.24 | -11.84% | ― | 1219.19% | 25.15% | |
45 Neutral | HK$12.76B | -36.96 | -15.75% | ― | 102.73% | 38.42% | |
40 Underperform | HK$9.14B | 61.57 | -21.42% | ― | 240.05% | -140.09% |
CARsgen Therapeutics Holdings Ltd. Corporate Events
CARsgen Therapeutics has granted 4,267,000 share options to 181 grantees under its Post-IPO Share Option Scheme, with an exercise price of HK$13.92 per share and a 10-year exercise period from the grant date. The options vest in four equal annual tranches between March 2027 and March 2030, forming part of a long-term incentive structure without additional performance targets but subject to clawback provisions in cases of misconduct.
The company said no financial assistance was provided to participants to acquire shares, underscoring a capital-light approach to employee equity participation. The move is likely aimed at strengthening talent retention and alignment of management and staff interests with shareholders, which could support CARsgen’s long-term growth strategy in the competitive biotech sector.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$10.00 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
CARsgen Therapeutics said its Hong Kong-listed shares have been added to the Southbound trading lists of both the Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect programs, effective March 9, 2026. The move allows eligible mainland Chinese investors to buy the stock directly via the Shanghai and Shenzhen exchanges’ connect platforms.
The company said the inclusion underscores market recognition of its core CAR-T business, regulatory compliance and share liquidity, and aligns with its long-term development strategy. Management expects the new access channel to mainland capital to boost trading liquidity, raise market attention and support the company’s broader capital markets development for the benefit of shareholders.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$10.00 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
CARsgen reported revenue of about RMB125.7 million for 2025, mainly driven by sales of its CAR-T therapy zevorcabtagene autoleucel, with revenue recognized on an ex-works delivery basis that can lag behind order intake. The company generated roughly RMB80 million in gross profit, citing cost advantages from self-manufacturing plasmids and vectors, and closed the year with cash and cash equivalents of around RMB1,123 million, despite ongoing R&D and capital spending.
The group’s net loss narrowed sharply to about RMB103 million in 2025 from roughly RMB798 million a year earlier, helped by a swing to net other gains, reduced research and development and administrative expenses, and higher gross profit as commercialization progressed. Adjusted net loss also declined substantially to around RMB78 million, and management expects to maintain cash of at least RMB1,000 million at end-2026, indicating a strengthened financial runway that could support its operations into 2030 and improve visibility for investors and partners.
The most recent analyst rating on (HK:2171) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
CARsgen Therapeutics Holdings Limited has scheduled a board meeting for March 6, 2026 to review and approve the Group’s annual results for the financial year ended December 31, 2025. The meeting will also address other corporate matters, signaling the upcoming disclosure of the company’s full-year financial performance, which will be closely watched by investors and other stakeholders for insights into its operational and strategic progress.
The announcement confirms the current composition of CARsgen’s board, including its executive, non-executive and independent non-executive directors, underscoring the governance framework overseeing these decisions. This routine but important step in the financial reporting cycle sets the timeline for the market to receive updated information on the company’s business trajectory and may influence investor sentiment once detailed results are made public.
The most recent analyst rating on (HK:2171) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
CARsgen Therapeutics will invest up to RMB370 million through its subsidiary CARsgen Diagnostics to establish an advanced commercial CAR T-cell manufacturing base in Jinshan District, Shanghai, in partnership with Shanghai Jingong Enterprise Development. The facility, created via customized renovation of industrial plants, is intended to support the commercialization of zevorcabtagene autoleucel, the NDA-stage satricabtagene autoleucel, and future allogeneic CAR T products, bolstering the company’s global competitiveness and aligning with supportive national and local biopharmaceutical policies.
The cooperation structure limits significant upfront capital expenditure, preserving cash flow for core R&D and market expansion while including a repurchase mechanism allowing CARsgen to regain full asset control within 20 years to ensure long-term production stability and flexible asset planning. Classified as a disclosable transaction under Hong Kong Listing Rules with relevant reporting and announcement requirements but exempt from shareholder approval, the deal underscores CARsgen’s strategic manufacturing expansion and is expected to strengthen its position in the global CAR T-cell therapy ecosystem and create long-term value for shareholders.
The most recent analyst rating on (HK:2171) stock is a Hold with a HK$13.50 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
CARsgen Therapeutics has issued a profit alert indicating a sharp narrowing of losses for the year ended 31 December 2025, driven mainly by growing revenue from the commercialization of its CAR-T therapy zevorcabtagene autoleucel in mainland China, the acceptance of the New Drug Application for satricabtagene autoleucel by China’s NMPA, favorable foreign exchange movements and significantly lower R&D spending on these two key assets. The group expects to report a net loss of no more than about RMB120 million, down from roughly RMB798 million a year earlier, and an adjusted net loss of not more than around RMB95 million versus approximately RMB789 million in 2024, underscoring improving operating leverage as its pipeline progresses, though the figures are based on unaudited management accounts and may differ from the final audited results.
The most recent analyst rating on (HK:2171) stock is a Hold with a HK$16.00 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.
CARsgen Therapeutics has extended the term of its existing share repurchase plan to run until the conclusion of its next annual general meeting, after having already bought back 7,627,000 shares under its 2025 repurchase mandate. Funded by non-IPO sources such as business development and interest income, the move is framed by the board as a signal that the company’s share price undervalues its long-term growth prospects and as a measure to enhance shareholder value. Separately, substantial shareholder YIJIE Biotech Holding Limited and its concert parties have increased their stake to about 38.2% of issued shares (excluding treasury shares), a development the board interprets as further market confidence in CARsgen’s long-term investment appeal, albeit with the caveat that future buybacks remain discretionary and subject to market conditions.
The most recent analyst rating on (HK:2171) stock is a Sell with a HK$14.92 price target. To see the full list of analyst forecasts on CARsgen Therapeutics Holdings Ltd. stock, see the HK:2171 Stock Forecast page.